Last reviewed · How we verify
MULTIHANCE:
At a glance
| Generic name | MULTIHANCE: |
|---|---|
| Sponsor | Bracco Diagnostics, Inc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. MultiHance is not approved for intrathecal use [see Warnings and Precautions (5.1) ] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination o
Common side effects
- Nausea
- Headache
Serious adverse events
- Convulsions
- Pulmonary edema
- Acute necrotizing pancreatitis
- Anaphylactoid reactions
- Anaphylactoid reaction with laryngeal spasm and dyspnea
Key clinical trials
- Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer (NA)
- Imaging in MGUS, SMM and MM (PHASE2)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer (PHASE2)
- Validity of Parametric MRI Using VIRADS (NA)
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis (PHASE2)
- Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases (PHASE4)
- Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MULTIHANCE: CI brief — competitive landscape report
- MULTIHANCE: updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI